title: Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
abstract: BACKGROUND
  The acid suppressive effects of omeprazole (OPZ) and lansoprazole (LPZ) are influenced by the CYP2C19 polymorphism. On the other hand, some investigators have reported that acid suppressive effect of rabeprazole (RPZ) was not significantly affected by CYP2C19. The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg.
  
  
  METHODS
  One hundred and three Japanese patients with RE were treated with daily oral administration of 10 mg RPZ. At 4 and 8 weeks after the start of treatment, healing of RE was evaluated endoscopically. The CYP2C19 genotype was investigated before the treatment.
  
  
  RESULTS
  At 4 weeks after the start of treatment, the healing rates for homo-extensive metabolizer, hetero-extensive metabolizer, and poor metabolizer patients were 83.3% (15/18), 77.3% (17/22), and 88.9% (8/9) [corrected] respectively, and at 8 weeks after the start of treatment, the healing rates were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), respectively. There were no significant differences in the healing rate of RE among the three genotypes at either 4 or 8 weeks after the start of treatment.
  
  
  CONCLUSIONS
  The therapeutic effects of 10 mg/day RPZ administration on RE may be uninfluenced by the CYP2C19 polymorphism.
authors.affiliation: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. kariizumi@int3.med.tohoku.ac.jp
authors.forename: Ken
authors.initials: K
authors.lastname: Ariizumi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ohara
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Koike
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Inomata
authors.forename: Katsunori
authors.initials: K
authors.lastname: Iijima
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sekine
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Noguchi
authors.forename: Koichi
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Eda
authors.forename: Shoichi
authors.initials: S
authors.lastname: Kayaba
authors.forename: Msashi
authors.initials: M
authors.lastname: Kawamura
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005755:Gastrins / Q000097:blood; D016481:Helicobacter Infections / Q000175:diagnosis; D006551:Hernia, Hiatal; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010435:Pepsinogens / Q000097:blood; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D064750:Rabeprazole; D014945:Wound Healing
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D005755:Gastrins; D010435:Pepsinogens; D064750:Rabeprazole; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19